Biomarkers /
RAD54L
Overview
RAD54L is altered in 0.74% of all cancers with colon adenocarcinoma, lung adenocarcinoma, endometrial endometrioid adenocarcinoma, breast invasive ductal carcinoma, and bladder urothelial carcinoma having the greatest prevalence of alterations [3].
The most common alterations in RAD54L are RAD54L Mutation (0.57%), RAD54L Amplification (0.09%), RAD54L Nonsense (0.05%), RAD54L Loss (0.03%), and RAD54L Fusion (0.02%) [3].
Biomarker-Directed Therapies
Clinical Trials
Significance of RAD54L in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.